Warith localize manufacturing of biological, cellular, and gene therapies in Iraq through 3 U.S. partnerships

We announce the conclusion of three strategic partnerships with specialized U.S. entities, aimed at localizing the manufacturing technologies for biopharmaceuticals and cell and gene therapies inside Iraq — a step described as a qualitative leap in the development of the national health sector. Dr. Haider Hamza Al-Abidi, Head of the Health and Medical Education Authority at the Holy Imam Hussain Shrine, said the agreements, concluded during his visit to the United States, include the provision of a modern bioreactor and its laboratory supplies in partnership with the global company Thermo Fisher, in addition to a clinical and training partnership with Boston Children's Hospital, the primary teaching affiliate of Harvard University, as well as an agreement with a partner specialized in transferring technologies locally to ensure the integration of the therapeutic system. He affirmed that the project builds on a supportive infrastructure, including bone marrow transplant procedures at Al-Mujtaba Hospital and the international accreditation of the Warith Foundation, noting that these partnerships will contribute to providing advanced treatments inside Iraq at prices lower than their global counterparts, and to ending reliance on sending patients abroad for specialized treatments, particularly children with cancers and complex diseases.